110 related articles for article (PubMed ID: 21936971)
1. Coverage with evidence development: merit for motherhood?
Koch P
Int J Technol Assess Health Care; 2011 Oct; 27(4):322; author reply 322-3. PubMed ID: 21936971
[No Abstract] [Full Text] [Related]
2. Coverage with evidence development: the Ontario experience.
Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
[TBL] [Abstract][Full Text] [Related]
3. KNOW ESSENTIALS: a tool for informed decisions in the absence of formal HTA systems.
Mathew JL
Int J Technol Assess Health Care; 2011 Apr; 27(2):139-50. PubMed ID: 21447262
[TBL] [Abstract][Full Text] [Related]
4. Technomics analysis: a matter of care before cost.
Hughes C
Adm Radiol J; 1997 Nov; 16(11):38-43. PubMed ID: 10178452
[No Abstract] [Full Text] [Related]
5. Decision tools in health care: focus on the problem, not the solution.
Liu J; Wyatt JC; Altman DG
BMC Med Inform Decis Mak; 2006 Jan; 6():4. PubMed ID: 16426446
[TBL] [Abstract][Full Text] [Related]
6. Coverage with evidence development for pharmaceuticals: a policy in evolution?
Lexchin J
Int J Health Serv; 2011; 41(2):337-54. PubMed ID: 21563627
[TBL] [Abstract][Full Text] [Related]
7. Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
Frederix GW; Haji Ali Afzali H; Dasbach EJ; Ward RL
Pharmacoeconomics; 2015 Aug; 33(8):777-81. PubMed ID: 25827099
[No Abstract] [Full Text] [Related]
8. Regarding probabilistic analysis and computationally expensive models: necessary and required?
Caro JJ; Getsios D; Möller J
Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
[No Abstract] [Full Text] [Related]
9. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
[TBL] [Abstract][Full Text] [Related]
10. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
Lewis JR; Kerridge I; Lipworth W
J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
[TBL] [Abstract][Full Text] [Related]
11. Case studies on forecasting for innovative technologies: frequent revisions improve accuracy.
Lerner JC; Robertson DC; Goldstein SM
Health Aff (Millwood); 2015 Feb; 34(2):311-8. PubMed ID: 25646112
[TBL] [Abstract][Full Text] [Related]
12. Assessing New Technologies in Aerosol Medicine: Strengths and Limitations.
Berlinski A
Respir Care; 2015 Jun; 60(6):833-47; discussion 847-9. PubMed ID: 26070578
[TBL] [Abstract][Full Text] [Related]
13. Marketplace. Assessing medical innovations: how health plans pick what technology to cover.
Moskowitz DB
Faulkner Grays Med Health; 1997 May; 51(21):suppl 2 p.. PubMed ID: 10167124
[No Abstract] [Full Text] [Related]
14. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
[TBL] [Abstract][Full Text] [Related]
15. An introduction to the methods of cost-effectiveness analysis.
Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
[TBL] [Abstract][Full Text] [Related]
16. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
17. How do cutting-edge treatments pass insurance muster?
Parrish M
Med Econ; 1998 May; 75(10):85-6, 89, 93-9. PubMed ID: 10179683
[No Abstract] [Full Text] [Related]
18. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
[TBL] [Abstract][Full Text] [Related]
19. IQWiG: an opportunity lost?
Jönsson B
Eur J Health Econ; 2008 Aug; 9(3):205-7. PubMed ID: 18496721
[No Abstract] [Full Text] [Related]
20. Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe.
Cave A; Kurz X; Arlett P
Clin Pharmacol Ther; 2019 Jul; 106(1):36-39. PubMed ID: 30970161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
